Design
Review
Authors
Loading...
May enable wider IPV access in eradication programs; leaves open optimal schedules and long-term durability.
Advances in biotechnology have made large-scale, cost-effective production of highly potent inactivated poliovirus vaccines feasible, with future potential for subunit vaccines.
Wezel et al. (1984) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: